Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841
Debt
Debt-to-Equity RatioN/A
Current Ratio8.03
Quick Ratio8.03
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales69.97
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.14
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net Margins-5,281.44%
Return on Equity-119.42%
Return on Assets-74.71%
Miscellaneous
Employees6
Outstanding Shares15,160,000
Market Cap$18.19
Neuralstem (NASDAQ:CUR) Frequently Asked Questions
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) released its earnings results on Tuesday, May, 15th. The company reported ($0.14) earnings per share for the quarter. Neuralstem had a negative net margin of 5,281.44% and a negative return on equity of 119.42%. View Neuralstem's Earnings History.
What price target have analysts set for CUR?
0 analysts have issued 12 month price targets for Neuralstem's stock. Their predictions range from $1.91 to $1.91. On average, they expect Neuralstem's share price to reach $1.91 in the next twelve months. This suggests a possible upside of 59.2% from the stock's current price. View Analyst Ratings for Neuralstem.
What is the consensus analysts' recommendation for Neuralstem?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuralstem in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include Applied Genetic Technologies (AGTC), Genocea Biosciences (GNCA), Champions Oncology (CSBR), Curis (CRIS), Aevi Genomic Medicine (GNMX), BioCardia (BCDA), Arsanis (ASNS), Proteon Therapeutics (PRTO), TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT), Oncobiologics (ONS), aTyr Pharma (LIFE) and Vical (VICL).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Mr. Richard J. Daly, Chairman, Pres, CEO & CFO (Age 57)
- Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
- Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
- Dr. David P. Recker, Chief Medical Officer (Age 60)
Has Neuralstem been receiving favorable news coverage?
Press coverage about CUR stock has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neuralstem earned a news impact score of 0.12 on Accern's scale. They also assigned news stories about the company an impact score of 46.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Neuralstem?
Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of CUR stock can currently be purchased for approximately $1.20.
How big of a company is Neuralstem?
Neuralstem has a market capitalization of $18.19 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.
How can I contact Neuralstem?
Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]
MarketBeat Community Rating for Neuralstem (NASDAQ CUR)
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
